share_log

Chimerix | 10-Q: Q2 2024 Earnings Report

Chimerix | 10-Q: Q2 2024 Earnings Report

Chimerix | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/13 06:27

Moomoo AI 已提取核心信息

Chimerix reported Q2 2024 revenues of $0.1 million and a net loss of $20.7 million ($0.23 per share), compared to revenues of $26,000 and a net loss of $18.6 million ($0.21 per share) in Q2 2023. Research and development expenses increased to $18.4 million from $16.9 million YoY, while general and administrative expenses remained relatively flat at $4.5 million. The company ended the quarter with $171.5 million in cash and investments.The company continues to advance its Phase 3 ACTION trial evaluating dordaviprone for H3 K27M-mutant diffuse glioma, with interim overall survival data expected in Q3 2025. The trial is enrolling patients across 140 sites in 13 countries. Additionally, Chimerix is pursuing Provisional Registration pathway for dordaviprone in Australia, with potential filing by year-end 2024.The company's second-generation compound ONC206 is progressing through dose escalation trials in CNS tumors, with over 75 patients enrolled to date. On June 27, Chimerix received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement and has until December 24, 2024 to regain compliance.
Chimerix reported Q2 2024 revenues of $0.1 million and a net loss of $20.7 million ($0.23 per share), compared to revenues of $26,000 and a net loss of $18.6 million ($0.21 per share) in Q2 2023. Research and development expenses increased to $18.4 million from $16.9 million YoY, while general and administrative expenses remained relatively flat at $4.5 million. The company ended the quarter with $171.5 million in cash and investments.The company continues to advance its Phase 3 ACTION trial evaluating dordaviprone for H3 K27M-mutant diffuse glioma, with interim overall survival data expected in Q3 2025. The trial is enrolling patients across 140 sites in 13 countries. Additionally, Chimerix is pursuing Provisional Registration pathway for dordaviprone in Australia, with potential filing by year-end 2024.The company's second-generation compound ONC206 is progressing through dose escalation trials in CNS tumors, with over 75 patients enrolled to date. On June 27, Chimerix received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement and has until December 24, 2024 to regain compliance.
Chimerix报告2024年第二季度收入为10万美元，净亏损为2070万美元（每股0.23美元），相比之下，2023年第二季度的收入为26000美元，净亏损为1860万美元（每股0.21美元）。研发费用同比增长至1840万美元，较去年1690万美元有所增加，而一般及行政费用保持相对平稳，为450万美元。公司在季度末拥有现金和投资共17150万美元。公司继续推进其评估dordaviprone用于H3 K2700万突变弥漫性胶质瘤的第三阶段ACTION试验，预计将在2025年第三季度公布中期整体生存数据。该试验在13个国家的140个地点招募患者。此外，Chimerix正在澳洲寻求dordavip...展开全部
Chimerix报告2024年第二季度收入为10万美元，净亏损为2070万美元（每股0.23美元），相比之下，2023年第二季度的收入为26000美元，净亏损为1860万美元（每股0.21美元）。研发费用同比增长至1840万美元，较去年1690万美元有所增加，而一般及行政费用保持相对平稳，为450万美元。公司在季度末拥有现金和投资共17150万美元。公司继续推进其评估dordaviprone用于H3 K2700万突变弥漫性胶质瘤的第三阶段ACTION试验，预计将在2025年第三季度公布中期整体生存数据。该试验在13个国家的140个地点招募患者。此外，Chimerix正在澳洲寻求dordaviprone的临时注册途径，预计将在2024年底前提交申请。公司的第二代化合物ONC206正在通过中枢神经系统肿瘤的剂量递增试验，目前已有超过75名患者入组。截至6月27日，Chimerix收到了来自纳斯达克的通知，关于未能遵守1.00美元的最低买盘价格要求，并必须在2024年12月24日之前恢复合规。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Forte Biosciences
    FBRX
    -- 8.500
    Plus Therapeutics
    PSTV
    -- 1.4300
    IO Biotech
    IOBT
    -- 1.180
    Celularity
    CELU
    -- 2.1300
    Tiziana Life Sciences
    TLSA
    -- 1.2249
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日